Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 136.81B +17.0% |
| Revenue (ttm) | 28.24B +8.5% |
| Net Income | 478.00M -87.7% |
| EPS | 1.37 -87.8% |
| Shares Out | 345.66M |
| PE Ratio | 288.91 |
| Forward PE | 23.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 552,807 |
| Average Volume | 466,226 |
| Open | 402.40 |
| Previous Close | 395.80 |
| Day's Range | 393.60 - 410.00 |
| 52-Week Range | 241.80 - 410.00 |
| Beta | 0.18 |
| RSI | 80.33 |
| Earnings Date | Feb 5, 2026 |
About STO:SOBI
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Full Company ProfileFinancial Performance
In 2025, STO:SOBI's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.
Financial StatementsNews
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) 2025 Q4 - Results - Earnings Call Presentation
Swedish Orphan Biovitrum AB reports Q4 results
European Commission Approves Sobi's Aspaveli for Rare Kidney Diseases
European Commission Approves Sobi's Aspaveli for Rare Kidney Diseases
SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) announced that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately 28.2 bi...
Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) 44th Annual J.P.
Sobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis
(RTTNews) - Swedish Orphan Biovitrum AB (publ) (SOBI.ST) or Sobi announced topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven sepsis (I...
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call December 15, 2025 2:00 AM ESTCompany ParticipantsGuido Oelkers - CEO & PresidentLydia...
Swedish Orphan Biovitrum AB (publ) (SWOBY) Arthrosi Therapeutics, Inc. - M&A Call - Slideshow
Sobi To Acquire Arthrosi Therapeutics
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech Holdings. Sobi will pay up t...
Sobi Announces CHMP's Positive Opinion For Aspaveli
(RTTNews) - Sobi (SOBI.ST) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of...
Positioning Barbados as the Caribbean's Life Sciences Hub
BRIDGETOWN, Barbados, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed a Letter of Intent to jointly esta...
Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (e mapalumab) data showed response rates in patients with MAS in Still's disease across MAS subtypes...
Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and ...
Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic Advancements Amid Challenges
Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) 2025 Q3 - Results - Earnings Call Presentation
Sobi Q3 Adj. EBITA Rises
(RTTNews) - Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion Swedish kronor compared to profit of 1.46 billion kronor, prior year. Loss per share was 8.32 kronor compared to p...
Sobi raises 2025 financial forecast after Q3 revenue jumps 21%
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs
KalVista Pharma (KALV) stock and Ionis Pharma (IONS) stock are in focus as the EU approve their rare disease drugs, Ekterly and Tryngolza, respectively. Read more here.
Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Swedish biopharmaceutical company Sobi announced Friday that TRYNGOLZA (olezarsen) has been approved in the European Union (EU) as an adjunct to diet...
Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout Call (Transcript)
Discover how NASP, an innovative uricase therapy, offers new hope for uncontrolled gout
Swedish Orphan Biovitrum AB (publ) - Special Call
Swedish Orphan Biovitrum AB (publ) - Special Call Company Participants Guido Oelkers - CEO & President Matthew Winfield Conference Call Participants Herbert S. B. Baraf Rehan Azeem Gonzalo Artiach Cas...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.